Holen Sie sich die Stockscreener-App
8.19
2.63%
0.22
Schlusskurs vom Vortag:
$7.97
Offen:
$7.94
24-Stunden-Volumen:
53,230
Relative Volume:
0.98
Marktkapitalisierung:
$50.68M
Einnahmen:
$2.19M
Nettoeinkommen (Verlust:
$-24.19M
KGV:
-0.9521
EPS:
-8.6017
Netto-Cashflow:
$-82.94M
1W Leistung:
+24.70%
1M Leistung:
+17.19%
6M Leistung:
-19.96%
1J Leistung:
+37.48%
1-Tages-Spanne:
$7.90
$8.635
1-Wochen-Bereich:
$6.73
$8.635
52-Wochen-Spanne:
$3.76
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Firmenname
Aligos Therapeutics Inc
Sektor
Branche
Telefon
(800) 466-6059
Adresse
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
8.19 | 49.32M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-19 | Fortgesetzt | Jefferies | Buy |
| 2025-08-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-08-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-01-06 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-23 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-01-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-09-09 | Eingeleitet | SVB Leerink | Outperform |
| 2021-05-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-11-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-10 | Eingeleitet | Jefferies | Buy |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Understanding the Setup: (ALGS) and Scalable Risk - Stock Traders Daily
ALGS.O PE Ratio & Valuation, Is ALGS.O Overvalued - Intellectia AI
ALGS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Tangible book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Net current asset value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Decliners Report: What are Aligos Therapeutics Incs technical support levels2026 Snapshot & Daily Volume Surge Signals - baoquankhu1.vn
Cash per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
ALGS PE Ratio & Valuation, Is ALGS Overvalued - Intellectia AI
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average PT from Analysts - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Raised to Strong-Buy at Jefferies Financial Group - Defense World
Earnings Risk: Can Aligos Therapeutics Inc continue delivering strong returns2026 Action & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
WestPark Capital initiates coverage of Aligos Therapeutics (ALGS) with buy recommendation - MSN
Insider Sell: Will Aligos Therapeutics Inc outperform its industry peers2026 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Bull Run: What analysts say about Aligos Therapeutics Inc stockWeekly Profit Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
The Technical Signals Behind (ALGS) That Institutions Follow - Stock Traders Daily
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peers2026 News Drivers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aligos Therapeutics (ALGS) 8th Annual MASH Investor Conference Summary - Quartr
If You Invested $1,000 in Aligos Therapeutics, Inc. (ALGS) - Stock Titan
ALGS Technical Analysis & Stock Price Forecast - intellectia.ai
Activity Recap: Can Aligos Therapeutics Inc weather a recessionTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
Jefferies Lowers Price Target for Aligos Therapeutics (ALGS) to $48 | ALGS Stock News - GuruFocus
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential - Investing.com India
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential By Investing.com - Investing.com South Africa
Nikhil Aneja Net Worth (2026) - GuruFocus
What is HC Wainwright’s Estimate for ALGS Q1 Earnings? - Defense World
Precision Trading with Aligos Therapeutics Inc. (ALGS) Risk Zones - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
Aligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike - Stock Titan
Aligos Therapeutics (ALGS) accounting officer granted 9,450 stock options at $7.03 - Stock Titan
Aligos Therapeutics (ALGS) awards 37,485 stock options to officer Calhoun - Stock Titan
Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating on ALGS with $50 Price Target | ALGS Stock News - GuruFocus
Dip Buying: Can Aligos Therapeutics Inc weather a recessionWeekly Earnings Recap & Risk Managed Trade Strategies - baoquankhu1.vn
Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen - Defense World
Aug Highlights: Can Aligos Therapeutics Inc weather a recessionMarket Rally & Daily Entry Point Alerts - baoquankhu1.vn
Aligos Therapeutics Earnings Report: Q4 Overview - Sahm
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results - Bitget
Aligos Therapeutics (ALGS) Reports Lower Q4 Revenue and Advances Key Studies - GuruFocus
ALIGOS THERAPEUTICS ($ALGS) Releases Q4 2025 Earnings - Quiver Quantitative
Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing - TradingView
Aligos Therapeutics Q4 net loss narrows - TradingView
Growth Report: Will Aligos Therapeutics Inc benefit from current market trendsM&A Rumor & High Win Rate Trade Alerts - baoquankhu1.vn
Big loss reduction as Aligos (NASDAQ: ALGS) advances HBV and obesity pipeline - Stock Titan
ALGS SEC FilingsAligos Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
A Peek at Aligos Therapeutics's Future Earnings - Benzinga
Aligos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
ALGS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aligos Therapeutics (ALGS) Expected to Announce Quarterly Earnings on Monday - Defense World
9 Pharma Trends To Watch In 2026 - Pharmaceutical Online
Finanzdaten der Aligos Therapeutics Inc-Aktie (ALGS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):